Hypertension, possible vascular protection and lercanidipine

Expert Review of Cardiovascular Therapy

Volumn 4, Issue 6, 2006, Pages 783-788

  Ram, C Venkata S ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Blood pressure goals; Calcium channel blockers; Hypertension; Lercanidipine; Target organ protection; Tolerability

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FELODIPINE; HYDROCHLOROTHIAZIDE; LACIDIPINE; LERCANIDIPINE; NIFEDIPINE; VERAPAMIL;

ADRENERGIC STIMULATION; ANKLE EDEMA; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; BLOOD VESSEL PERMEABILITY; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE MARKER; DRUG ACCUMULATION; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; HEADACHE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INOTROPISM; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; LIPOPHILICITY; MONOTHERAPY; OBESITY; PUBLIC HEALTH; REMISSION; RENAL PROTECTION; SIDE EFFECT; STROKE; TACHYCARDIA; TARGET ORGAN; TREATMENT OUTCOME; VASCULAR RESISTANCE; VASCULAR TISSUE; VASODILATATION;

CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; DRUG THERAPY, COMBINATION; EDEMA; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS;

EID: 33845896000     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.4.6.783     Document Type: Article

References (37)

1. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42, 1206-1252 (2003).
2. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 21, 1011-1052 (2003).
3. Agodoa L, Appel L, Bakris G, on behalf of the African American Study of Kidney Disease and hypertension 9AASK Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. JAMA 285, 2719-2728 (2001).
4. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 92, 1326-1331 (1995).
5. Psaty BM, Heckbert SR, Koepsell TD et al. This risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 274, 620-625 (1995).
6. Angelico P, Guarneri L, Leonardi A, Testa R. Vascular-selective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues. J. Pharm. Pharmacol. 51, 709-714 (1995).
7. Herbette LG, Vecchiarelli M, Sartani A, Leonardi A. Lercanidipine. Short plasma half-life, long duration of action and high cholesterol tolerance. Blood Press. 7(Suppl. 2), 10-17 (1998).
8. Grassi G, Seravalle G, Turri C, Bolla G, Mancia G. Short- versus long-term effects of different dihydropyridines on sympathetic and baroreflex function in hypertension. Hypertension 41(3), 558-562 (2003).
9. Fogari R, Mugellini A, Zoppi A et al. Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension. Am. J. Hypertens. 16, 596-599 (2003).
10. Barrios V, Navarro A, Esteras A et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study. Eficacia de Lercanidipino y su Perfil de Seguridad. Blood Press. 11, 950-100 (2002).
11. Cafiero M, Giasi M. Long-term (12 month) treatment with lercanidipine in patients with mild to moderate hypertension. J. Cardiovasc. Pharmacol. 29(Suppl. 2), S45-S49 (1997).
12. Marx A, Lichtenthal A, Milbredt C et al. Effect of anthypertensive therapy with a new third generation calcium antagonist lercanidipine on pateints with concomitant diseases. J. Hypertens. 22(Suppl. 2), S236 (2004).
13. Martell N, Lopez-Eady MD, Castro P et al Modifications of the pulse pressure in elderly hypertensives treated with lercanidipine. J. Hypertens. 22(Suppl. 2), S121 (2004).
14. DeGiorgio L, Orlandini F, Malasoma P. Zappa A. Double-blind, crossover study of lercanidipine versus amlodipine in the treatment of mild-to-moderate essential hypertension. Curr. Therapeut. Res. 60, 511-520 (1999).
15. Cesarone MR, Incandela L, Ledda A et al. Pressure and microcirculatory effects of treatment with lercanidipine in hypertensive patients and in vascular patients with hypertension. Angiology 51, S53-S63 (2000).
16. Cleophas TJ, van Ouwerkerk BM, van der Meulen J, Zwinderman AH. Diabetics with hypertension not controlled with ACE inhibitors; alternate therapies. Angiology 52, 469-475 (2001).
17. Romito R, Pansini MI, Perticone F, Antonelli G, Pitzalis M, Rizzon P. Comparative effect of lercanidipine, felodipine, and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercanidipine in ADults (LEAD) Study. J. Clin. Hypertens. 5, 249-253 (2003).
18. Leonetti G, Magnani B, Pessina AC et al. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am. J. Hypertens. 15, 932-940 (2002).
19. Fogari R, Malmani GD, Zoppi A et al. Comparative effect of lercanidipine and nifedipine gastrointestinal therapeutic system on ankle volume and subcutaneous interstitial pressure in hypertensive patients: a double-blind randomized, parallel-group study. Curr. Ther. Res. Clin. Exp. 61, 850-862 (2000).
20. Ram CVS. Usefulness of lercanidipine, a new calcium antagonist, for systemic hypertension. Am. J. Cardiol. 89, P214 (2002).
21. Agrawal R, Marx A, Haller H. Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. J. Hypertens. 24, 185-192 (2006).
22. Roma J, Sobrino, J, Soler-Amigo J et al. Treatment with lercanidipine during six months in hypertensive elderly patients (More than sixty years). J. Hypertens. 20(Suppl. 4), S391 (2004).
23. Ninci MS, Magliocca R, Malliani A. Efficacy and tolerability of lercanidipine in elderly patients with mild to moderate hypertension in a placebo-controlled, double-blind study. J. Cardiovasc. Pharmacol. 29, S40-S44 (1997).
24. Millar-Craig M, Shaffu B, Greenough A et al. Lercanidipine vs lacidipine in isolated systolic hypertension. J. Hum. Hypertens. 17, 799-806 (2003).
25. Barbagallo M, Barbagallo Sangiorgi G. Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension. Aging (Milano) 12(5), 375-379 (2000).
26. Viviani GL, Lercanidipine in type II diabetic patients with mild to moderate arterial hypertension. J. Cardiovasc. Pharmacol. 40, 133-139 (2002).
27. Dalla Vestra M, Pozza G, Mosca A et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipine. Diabetes Nutr. Metab. 11, 259-266 (2004).
28. Menne J, Park JK, Agrawal R et al. Cellular and molecular mechanisms of tissue protection by lipophilic calcium channel blockers. FASEB J. 20, 994-996 (2006).
29. Sarafidis P, Lasaridis A, Hatzistavri L et al. The effect of telmisartan and lercanidipine on blood pressure and insulin resistance in hypertensive patients. Rev. Clin. Pharmacol. Pharmacokinet. Int. 18, 60-66 (2004).
30. Robles NR, Ocon J, Gomez CF et al. Lercanidipine in patients with chronic renal failure: The Zafra study. Ren. Fail. 27, 73-80 (2005).
31. Robies NR, Pastor L, Manjon M et al. Lercanidipine in diabetic patients with renal failure. Nefrologia 24, 338-343 (2004).
32. Sabbatini M, Leonardi A, Testa R, Viatoli L, Amenta F. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension 35, 775-779 (2000).
33. Fogari R, Mugelini A, Corradi L et al. Efficacy of lercanidipine vs losartan on left ventricular hypertrophy in hypertensive type 2 diabetic patients (abstr). J. Hypertens. 18(Suppl. 2), S63 (2000).
34. Barrios V, Escobar C, Navarro et al. Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: the LAURA study. Int. J. Clin. Pract. 60, 1364-1370 (2006).
35. Borghi C, Prandin MG, Dormi A, Ambrosioni E. Improved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial. Blood Press. 1(Suppl.), 14-21 (2003).
36. Lund-Johansen P, Stranden E, Helberg S et al. Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine. J. Hypertens. 21, 1003-1010 (2003).
37. Pedrinelli R, Dell'omo G, Nutl M, Menegato, A, Balbarini A, Mariani M. Heterogeneous effect of calcium antagonists on leg edema: a comparison of amlodipine versus lercanidipine in hypertensive patients. J. Hypertens. 21, 1969-1973 (2003).